financetom
Business
financetom
/
Business
/
Corus Entertainment Q2 Adjusted Loss Surges, Misses Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Corus Entertainment Q2 Adjusted Loss Surges, Misses Estimates
Apr 11, 2025 4:55 AM

07:37 AM EDT, 04/11/2025 (MT Newswires) -- Corus Entertainment (CJR-B.TO) on Friday reported its second-quarter adjusted net loss widened and came in worse than the consensus estimate compiled by FactSet.

For the three months ended Feb. 28, the company reported an adjusted net loss attributable to shareholders of $42.7 million, or $0.21 per share, compared with a loss of $5.9 million, or $0.03 per share, a year earlier. The consensus estimate compiled by FactSet was for a loss per share of $0.12.

Consolidated revenue decreased 10% to $270.4 million in Q2 compared with $299.5 million, a year-ago. Revenue was in-line with analyst expectations for the period.

"Our television advertising revenue was modestly ahead of our outlook for the second quarter... at the same time, we recognize that the industry landscape remains challenging with limited visibility," said Corus Co-Chief Executive and Chief Financial Officer John Gossling. "As such, importantly, we have taken significant steps to progress our capital and debt plan, and our updated credit facility provides enhanced stability as we pursue further right-sizing initiatives and targeted growth opportunities to create a more sustainable future."

The company expects over-supply of premium digital video inventory from foreign competitors and continued generally lower demand for linear advertising in the third quarter. Year-over-year percentage declines in Television advertising revenue in Q3 are expected to be in the mid-teens.

Corus added that it will continue with its implementation of additional cost reduction initiatives and expects general and administrative expenses to decline in the range of 5% to 10% for Q3, compared with the prior year.

Shares of the company closed down 4.2% to $0.115 on Thursday on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Natera Insider Sold Shares Worth $2,269,928, According to a Recent SEC Filing
Natera Insider Sold Shares Worth $2,269,928, According to a Recent SEC Filing
Feb 3, 2025
03:09 AM EST, 02/03/2025 (MT Newswires) -- Steven Leonard Chapman, Director, Chief Executive Officer and President, on January 29, 2025, sold 13,685 common shares in Natera ( NTRA ) for $2,269,928. Following the Form 4 filing with the SEC, Chapman has control over a total of 253,944 shares of the company, with 253,944 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1604821/000141588925002621/xslF345X05/form4-01312025_090101.xml ...
Tempus AI Insider Sold Shares Worth $13,278,632, According to a Recent SEC Filing
Tempus AI Insider Sold Shares Worth $13,278,632, According to a Recent SEC Filing
Feb 3, 2025
03:10 AM EST, 02/03/2025 (MT Newswires) -- Eric P Lefkofsky, 10% Owner, Director, Chief Executive Officer and Chairman, on January 29, 2025, sold 238,800 Class A common shares in Tempus AI ( TEM ) for $13,278,632. Following the Form 4 filing with the SEC, Lefkofsky has control over a total of 48,757,318 shares of the company, with 5,532,987 shares held...
Alkermes Insider Sold Shares Worth $3,234,382, According to a Recent SEC Filing
Alkermes Insider Sold Shares Worth $3,234,382, According to a Recent SEC Filing
Feb 3, 2025
03:12 AM EST, 02/03/2025 (MT Newswires) -- Craig C. Hopkinson, Executive Vice President, Research & Development, Chief Medical Officer, on January 30, 2025, sold 100,918 ordinary shares in Alkermes ( ALKS ) for $3,234,382. Following the Form 4 filing with the SEC, Hopkinson has control over a total of 44,290 shares of the company, with 44,290 shares held directly. SEC...
EssilorLuxottica receives FDA clearance for its Nuance audio glasses
EssilorLuxottica receives FDA clearance for its Nuance audio glasses
Feb 3, 2025
ROME (Reuters) - EssilorLuxottica said on Monday it received a green light from the U.S. Food and Drug Administration (FDA) for its over-the-counter Nuance audio glasses. Nuance - which pairs hearing solutions with prescription glasses - will be available in the U.S. and in Italy in the first quarter of the year and in other European countries, including France, Germany...
Copyright 2023-2025 - www.financetom.com All Rights Reserved